Home › Funds › Parkman Healthcare Partners LLC › XENE

Parkman Healthcare Partners LLC position in XENE

XENON PHARMACEUTICALS INC · Health Care

Parkman Healthcare Partners LLC reported holding 397,379 shares of XENE (XENON PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$24.0M, representing 2.46% of its reported portfolio and ranking #11 among its reported holdings. Parkman Healthcare Partners LLC has disclosed XENE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)397.38K sh
Reported value held$23.99M
Portfolio Weight2.46%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Parkman Healthcare Partners LLC's XENE position evolved

Parkman Healthcare Partners LLC first disclosed a stake in XENE in Q3 2023 at 216,644 shares (US$7.4M). The position peaked in Q1 2026 at 497,035 shares, worth US$28.9M. Across 12 filings, Parkman Healthcare Partners LLC increased the stake 4 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 397,379 shares valued at US$24.0M — a reduction of -99,656 shares quarter over quarter.. Notable position changes include a 36% increase in Q4 2023 (shares fell 7% over the following quarter), a 222% increase in Q1 2026 (shares rose 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 216.64K $7.40M New
Q4 2023 294.79K $13.58M Add
Q1 2024 223.94K $9.64M Reduce
Q2 2024 209.29K $8.16M Reduce
Q3 2024 191.66K $7.55M Reduce
Q4 2024 193.00K $7.57M Add
Q1 2025 174.58K $5.86M Reduce
Q2 2025 150.37K $4.71M Reduce
Q3 2025 176.14K $7.07M Add
Q4 2025 154.18K $6.91M Reduce
Q1 2026 497.04K $28.90M Add
Q2 2026 397.38K $23.99M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XENE and 13F data

XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 44 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$348.7M), Polar Capital Holdings Plc (US$275.9M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$266.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XENE

All XENE fund holders →

FAQ

How long has Parkman Healthcare Partners LLC held XENE?

Parkman Healthcare Partners LLC has disclosed XENE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Parkman Healthcare Partners LLC's current position in XENE?

As of Q2 2026, Parkman Healthcare Partners LLC holds 397.38K shares of XENE (XENON PHARMACEUTICALS INC), valued at $23.99M, representing 2.46% of its reported portfolio and ranking #11.

Has Parkman Healthcare Partners LLC been buying or selling XENE?

In the latest 13F filing (Q2 2026), Parkman Healthcare Partners LLC reduced its position in XENE. The position peaked in Q1 2026 at 497.04K shares.

Which other funds hold XENE?

Other major institutional holders of XENE include Avoro Capital Advisors LLC, Polar Capital Holdings Plc, DRIEHAUS CAPITAL MANAGEMENT LLC, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.